Literature DB >> 9790453

Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis.

U Volta1, L De Franceschi, N Molinaro, F Cassani, L Muratori, M Lenzi, F B Bianchi, A J Czaja.   

Abstract

Celiac disease has been associated with autoimmune disorders, but its frequency in autoimmune hepatitis is unknown. Sera from 157 patients with type 1 autoimmune hepatitis, 24 patients with type 2 autoimmune hepatitis, 62 patients with primary biliary cirrhosis, 30 patients with chronic hepatitis B, and 80 patients with chronic hepatitis C were tested for immunoglobulin A anti-endomysial antibodies by indirect immunofluorescence and immunoglobulin A and G antibodies to gliadin by enzyme immunoassay. Duodenal biopsy evaluation was recommended in patients seropositive for immunoglobulin A anti-endomysial antibodies. Immunoglobulin A anti-endomysial antibodies were present in eight of the 181 patients with autoimmune hepatitis (4%), including six with type 1 disease (4%) and two with type 2 disease (8%). Immunoglobulin A antibodies to gliadin were found in six of these eight patients, but they were also present in two others, including one patient with chronic hepatitis C. Five of the eight patients with immunoglobulin A antiendomysial antibodies, including three patients with no gastrointestinal symptoms, had duodenal biopsies and subtotal villous atrophy was present in all of them. No patient with primary biliary cirrhosis or chronic viral hepatitis had antiendomysial antibodies. The presence of celiac disease in autoimmune hepatitis is high (at least one in 36 patients) and it is predominantly asymptomatic. Screening with anti-endomysial and anti-gliadin antibodies should be performed and results confirmed with intestinal biopsy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790453     DOI: 10.1023/a:1026650118759

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  IgA antiendomysial antibody test. A step forward in celiac disease screening.

Authors:  U Volta; N Molinaro; M Fusconi; F Cassani; F B Bianchi
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  HLA-DR antigens in primary biliary cirrhosis: lack of association.

Authors:  M F Bassendine; P J Dewar; O F James
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

3.  Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies.

Authors:  A Lerner; V Kumar; T C Iancu
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

4.  The many faces of celiac disease.

Authors:  C Halsted
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

5.  Associations between alleles of the major histocompatibility complex-encoded ABC transporter gene TAP2, HLA class II alleles, and celiac disease susceptibility.

Authors:  M R Tighe; M A Hall; E Cardi; A Ashkenazi; J S Lanchbury; P J Ciclitira
Journal:  Hum Immunol       Date:  1994-01       Impact factor: 2.850

6.  Human umbilical cord as substrate for IgA antiendomysial antibodies allows large scale screening for celiac sprue.

Authors:  U Volta; N Molinaro; L De Franceschi; F B Bianchi
Journal:  J Clin Gastroenterol       Date:  1996-07       Impact factor: 3.062

7.  Coeliac disease and autoimmune thyroid disease.

Authors:  C E Counsell; A Taha; W S Ruddell
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

8.  Elevated serum aminotransferase activity as an early manifestation of gluten-sensitive enteropathy.

Authors:  P Vajro; A Fontanella; M Mayer; A De Vincenzo; L M Terracciano; M D'Armiento; R Vecchione
Journal:  J Pediatr       Date:  1993-03       Impact factor: 4.406

9.  Osteoporosis in treated adult coeliac disease.

Authors:  X A McFarlane; A K Bhalla; D E Reeves; L M Morgan; D A Robertson
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

10.  Female fertility, obstetric and gynaecological history in coeliac disease. A case control study.

Authors:  K S Sher; J F Mayberry
Journal:  Digestion       Date:  1994       Impact factor: 3.216

View more
  54 in total

1.  Spectrum of autoantibodies in celiac patients and relatives.

Authors:  S R da Rosa Utiyama; L M da Silva Kotze; R M Nisihara; R F Carvalho; E G de Carvalho; M G de Sena; I J de Messias Reason
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 2.  Celiac disease: diagnostic criteria in progress.

Authors:  U Volta; V Villanacci
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

3.  Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.

Authors:  Albert J Czaja; Zakera Shums; Peter T Donaldson; Gary L Norman
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

4.  Systemic autoimmune disorders associated with celiac disease.

Authors:  Jason Slate; Perry Hookman; Jamie S Barkin; Richard S Phillips
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 5.  Hepatobiliary and pancreatic disorders in celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

6.  Celiac sprue: a unique autoimmune disorder.

Authors:  Shadi Rashtak; Eric V Marietta; Joseph A Murray
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

7.  The changing face of celiac disease.

Authors:  R Lad; K Jacobson
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

Review 8.  Celiac disease and autoimmunity in the gut and elsewhere.

Authors:  Susan H Barton; Joseph A Murray
Journal:  Gastroenterol Clin North Am       Date:  2008-06       Impact factor: 3.806

Review 9.  Coeliac disease and liver dysfunction.

Authors:  S Davison
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

10.  Hypogalactosylation of serum IgG in patients with coeliac disease.

Authors:  J A Cremata; L Sorell; R Montesino; R Garcia; M Mata; G Cabrera; J A Galvan; G Garcia; R Valdes; J A Garrote
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.